Welcome to our quarterly update relating to biologics and biosimilars, including post-grant and patent litigation challenges to blockbuster biologics. Since the enactment of the Biologics Price Competition and Innovation Act (BPCIA), 67 biosimilars have been approved, 43 of which have launched. Notably, since our last update, Amgen filed suit against Accord Biopharma, Inc., alleging infringement of 33 patents relating to Accord Biopharma’s biosimilars to PROLIA and XGEVA.
Please see full publication below for more information.
